Dr Lal PathLabs 1:1 Bonus Issue Record Date Set for 19 December 2025

Dr. Lal PathLabs has firmed up the record date for its proposed 1:1 bonus issue, giving existing shareholders clarity on eligibility, while the stock trades below key moving averages and analysts share mixed technical views on the near-term trajectory for Dr. Lal PathLabs shares.

The Board has selected Friday, December 19, 2025, as the record date that will decide which investors receive additional shares, and has also outlined the deemed allotment date and expected credit timeline, alongside details of the number of shares and funding source for this Dr. Lal PathLabs bonus issue.

"In this regard, we wish to inform you that the Board of Directors today i.e. December 12, 2025, through Circular Resolution fixed "Friday, December 19, 2025" as the Record Date for the purpose of determining the eligibility of the Members of the Company for issuing bonus equity shares. Further, in accordance with SEBI circular no. CIR/CFD/PoD/2024/122 dated September 16, 2024, the deemed date of allotment of bonus equity shares shall be "Monday, December 22, 2025," said Dr. Lal PathLabs in a stock exchange filing.

On December 8, 2025, the company had already informed stock exchanges that the Board approved a bonus share ratio of 1:1, so every eligible name in the Register of Members and the list from NSDL and CDSL on the record date for the Dr. Lal PathLabs bonus issue will receive one fully paid equity share of face value Rs 10 for every existing share held.

The Dr. Lal PathLabs bonus issue will involve issuing 8,37,75,510 new equity shares, giving a total face value of Rs 83.77 crore, and the company plans to transfer Rs 83,77,55,100 from its Securities Premium Account to support this capitalisation, with the management indicating that the bonus shares are expected to be credited or allotted to eligible investors by December 30, 2025, or within two months of Board approval.

The stock carries a market capitalisation of Rs 24,067.87 crore, and Dr. Lal PathLabs shares ended at Rs 2,872.90 on the BSE on Friday, December 12, while the healthcare counter hit a 52-week high of Rs 3,542.60 on September 19, 2025, and touched a 52-week low of Rs 2,295.10 on March 3, 2025.

Dr. Lal PathLabs bonus issue context, share price levels and technical view

As of December 12, 2025, Trendlyne data shows Dr. Lal PathLabs Ltd. (LALPATHLAB) falls in the "Mid-range Performer" category, with sentiment leaning negative, since the share price near Rs 2,874.50 trades below the 200-day Simple Moving Average of Rs 2,948.1 and the 50-day Simple Moving Average of Rs 3,096.2, hinting at weakness in the broader trend.

The Relative Strength Index stands at 31.5, suggesting mid-range strength, but the Money Flow Index at 20.3 signals an oversold zone and strong recent selling, and despite this pressure and the Dr. Lal PathLabs bonus issue announcement, the share still trades 25.33% above its 52-week low, while the 1-year Beta reflects very low volatility.

The key price and indicator levels around the Dr. Lal PathLabs share price and bonus issue context are summarised below.

Metric	Value
Market capitalisation	Rs 24,067.87 crore
Last BSE close (December 12, 2025)	Rs 2,872.90
Current trading reference price	Rs 2,874.50
52-week high (19/09/2025)	Rs 3,542.60
52-week low (03/03/2025)	Rs 2,295.10
200-day SMA	Rs 2,948.1
50-day SMA	Rs 3,096.2
RSI	31.5
MFI	20.3

Dr. Lal PathLabs target price views and trading levels

"Dr Lal PathLabs is showing steady bullish momentum, holding firmly above its key support zone near Rs 2,800. The stock is forming higher lows on the daily chart, indicating sustained buying interest. A decisive move above Rs 2,900 could trigger further upside toward Rs 3,000, while Rs 2,750 remains an important support level," commented technical analyst Riyank Arora of Mehta Equities Ltd.

"Dr Lal Path Labs is bearish & also extremely oversold with next support at 2742. Investors should buy only if Daily close is above resistance of 2954 could lead to a target of 3309 in the near term," recommended A R Ramachandran, Independent SEBI-registered Research Analyst, Tips2trades.

"Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred to as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions."

For investors tracking Dr. Lal PathLabs shares, the confirmed 1:1 bonus structure, defined record and allotment dates, technical readings around key support and resistance levels, and differing analyst targets together present a detailed picture of current conditions, but any investment choice still depends on individual risk assessment and advice from licensed professionals.